Amylyx’s ALS Treatment Candidate Gets Priority Review

By PacConAdmin | December 29, 2021

Amylyx Pharmaceuticals has scored a priority review by the FDA for AMX0035 (sodium phenylbutyrate and taurursodiol) as a treatment for amyotrophic lateral sclerosis (ALS).
Source: Drug Industry Daily

Posted in Drug Industry Daily